Hepatosplenomegaly associated with chronic malaria exposure: evidence for a pro-inflammatory mechanism exacerbated by schistosomiasis.
In sub-Saharan Africa, chronic hepatosplenomegaly, with palpable firm/hard organ consistency, is common, particularly among school-aged children. This morbidity can be caused by long-term exposure to malaria, or by Schistosoma mansoni, and it is exacerbated when these two occur together. Although immunological mechanisms probably underlie the pathogenic process, these mechanisms have not been identified, nor is it known whether the two parasites augment the same mechanisms or induce unrelated processes that nonetheless have additive or synergistic effects. Kenyan primary schoolchildren, living in a malaria/schistosomiasis co-transmission area, participated in cross-sectional parasitological and clinical studies in which circulating immune modulator levels were also measured. Plasma IL-12p70, sTNF-RII, IL-10 and IL-13 levels correlated with relative exposure to malaria, and with hepatosplenomegaly. Soluble-TNF-RII and IL-10 were higher in children infected with S. mansoni. Hepatosplenomegaly caused by chronic exposure to malaria was clearly associated with increased circulating levels of pro-inflammatory mediators, with higher levels of regulatory modulators, and with tissue repair cytokines, perhaps being required to control the inflammatory response. The higher levels of regulatory modulators amongst S. mansoni infected children, compared to those without detectable S. mansoni and malarial infections, but exposed to malaria, suggest that S. mansoni infection may augment the underlying inflammatory reaction.
Wilson
S
S
Department of Pathology, University of Cambridge, Cambridge, UK. sw320@cam.ac.uk
Jones
F M
FM
Mwatha
J K
JK
Kimani
G
G
Booth
M
M
Kariuki
H C
HC
Vennervald
B J
BJ
Ouma
J H
JH
Muchiri
E
E
Dunne
D W
DW
D000293:Adolescent; D000818:Animals; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D006529:Hepatomegaly / Q000453:epidemiology* / Q000276:immunology / Q000469:parasitology*; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000276:immunology / Q000469:parasitology; D016753:Interleukin-10 / Q000097:blood; D018664:Interleukin-12 / Q000097:blood; D018793:Interleukin-13 / Q000097:blood; D007630:Kenya / Q000453:epidemiology; D008222:Lymphokines / Q000097:blood; D016778:Malaria, Falciparum / Q000097:blood / Q000150:complications* / Q000276:immunology; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood; D012555:Schistosomiasis mansoni / Q000097:blood / Q000150:complications* / Q000276:immunology; D013163:Splenomegaly / Q000453:epidemiology* / Q000276:immunology / Q000469:parasitology*
D018793:Interleukin-13; D008222:Lymphokines; D047889:Receptors, Tumor Necrosis Factor, Type II; D016753:Interleukin-10; D018664:Interleukin-12